Hovione Technology acquires global rights to new pulmonary inhaler device15 Apr 2019
The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.
Hovione Technology has secured global rights to develop and commercialize a new ultra-affordable, multi-use blister-based dry powder inhaler (DPI) patented by inventor Dr Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.
The Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments. It can accommodate a single or double blister configuration, enabling ultra-affordable drug therapies at global scale.
Papillon unlocks a paradigm shift for pharmaceutical companies developing new inhaled drugs: unit dose costs competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices.
Hovione Technology’s CEO Peter Villax said: “This is a strategic DPI development for Hovione Technology which emphasizes our long-term commitment to offer market access to a portfolio of innovative inhalers that maximize simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialization of this innovative blister DPI”.
Hovione Technology has a co-promotional agreement with API manufacturer Hovione and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.
Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment
4 Dec 2019
Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.Read more
Eli Lilly unveils shared innovation laboratory in San Francisco
3 Dec 2019
Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.Read more
Ground-breaking work creates novel oil-in-water nanoemulsions
3 Dec 2019
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.Read more
UK experiences a 'baby boom' of new life sciences ventures
2 Dec 2019
Unprecedented levels of investment cited as a major force driving the expansion.Read more
Recipharm joins the AMR Industry Alliance
15 Nov 2019
Marks the latest step in the company’s ongoing efforts to engage with other organisations working to tackle antimicrobial resistance.Read more
In vitro disease models that could lead to new therapies
14 Nov 2019
New models can help researchers investigate disease development and find new treatment approaches.Read more
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies
8 Nov 2019
But personalized medicines will require new logistics and manufacturing systems.Read more
Recipharm launches new service to support companies with QC and analytical requirements
1 Nov 2019
Services including method development, method validation, and stability program design and implementation.Read more
FDA approves first and only medicine in a new class of acute treatment for migraine
15 Oct 2019
The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.Read more
Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio
14 Oct 2019
Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation